S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:TNDM

Tandem Diabetes Care - TNDM Stock Forecast, Price & News

$48.82
-2.73 (-5.30%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$48.30
$51.69
50-Day Range
$48.82
$68.97
52-Week Range
$48.30
$155.86
Volume
1.08 million shs
Average Volume
786,663 shs
Market Capitalization
$3.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$103.36

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
111.7% Upside
$103.36 Price Target
Short Interest
Healthy
6.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.28mentions of Tandem Diabetes Care in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$656,507 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.23) to $0.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

179th out of 1,116 stocks

Surgical & Medical Instruments Industry

15th out of 112 stocks

TNDM stock logo

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TNDM shares. Wells Fargo & Company cut shares of Tandem Diabetes Care from an "overweight" rating to an "underweight" rating and cut their price target for the stock from $82.00 to $49.00 in a report on Tuesday, August 9th. Cowen reduced their target price on shares of Tandem Diabetes Care from $141.00 to $107.00 in a research report on Thursday, August 4th. StockNews.com downgraded shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research note on Friday, July 1st. Raymond James dropped their price objective on Tandem Diabetes Care from $125.00 to $90.00 and set an "outperform" rating on the stock in a research note on Thursday, August 4th. Finally, Piper Sandler lowered their target price on Tandem Diabetes Care from $120.00 to $80.00 and set an "overweight" rating for the company in a report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $103.36.

Tandem Diabetes Care Stock Down 5.3 %

Shares of NASDAQ:TNDM traded down $2.73 during mid-day trading on Friday, reaching $48.82. 1,079,977 shares of the company were exchanged, compared to its average volume of 786,663. Tandem Diabetes Care has a 1 year low of $48.30 and a 1 year high of $155.86. The firm has a 50-day moving average of $58.97 and a 200 day moving average of $86.00. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of -221.91 and a beta of 0.80. The company has a quick ratio of 5.36, a current ratio of 6.00 and a debt-to-equity ratio of 0.63.

Insiders Place Their Bets

In other news, COO David B. Berger sold 10,097 shares of the firm's stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $65.02, for a total value of $656,506.94. Following the sale, the chief operating officer now directly owns 2,457 shares in the company, valued at approximately $159,754.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.20% of the stock is currently owned by corporate insiders.

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Stock News Headlines

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast:
"Prepare for Five Years of Famine". Click here for the name of the one ticker you need to protect yourself. pixel
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Tandem Diabetes Care (NASDAQ:TNDM) PT Lowered to $80.00
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Cut to $150.00
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Cut to $90.00
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings
11/03/2021
Today
8/19/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,000
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$103.36
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+111.7%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$15.57 million
Pretax Margin
-1.62%

Debt

Sales & Book Value

Annual Sales
$702.80 million
Cash Flow
$0.48 per share
Book Value
$7.00 per share

Miscellaneous

Free Float
62,808,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
0.80

Social Links


Key Executives

  • Mr. John F. SheridanMr. John F. Sheridan (Age 67)
    Pres, CEO & Director
    Comp: $1.6M
  • Ms. Leigh A. VossellerMs. Leigh A. Vosseller (Age 49)
    Exec. VP, CFO & Treasurer
    Comp: $764.64k
  • Mr. David B. Berger Esq. (Age 52)
    Exec. VP & COO
    Comp: $765.11k
  • Ms. Susan M. MorrisonMs. Susan M. Morrison (Age 43)
    Exec. VP & Chief Admin. Officer
    Comp: $764.35k
  • Mr. Brian B. HansenMr. Brian B. Hansen (Age 54)
    Exec. VP & Chief Commercial Officer
    Comp: $781.22k
  • Ms. Elizabeth Anne GasserMs. Elizabeth Anne Gasser (Age 46)
    Exec. VP & Chief Strategy Officer
    Comp: $764.64k
  • Mr. Rick A. Carpenter (Age 59)
    Chief Technical Officer
  • Ms. Shannon M. Hansen (Age 56)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. Ross Sylvia
    VP of Marketing
  • Mr. Tom Fox
    Sr. VP of HR & Organizational Devel.













TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2022?

7 analysts have issued 12-month price targets for Tandem Diabetes Care's stock. Their TNDM share price forecasts range from $49.00 to $150.00. On average, they expect the company's share price to reach $103.36 in the next twelve months. This suggests a possible upside of 111.7% from the stock's current price.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2022?

Tandem Diabetes Care's stock was trading at $150.52 at the beginning of 2022. Since then, TNDM shares have decreased by 67.6% and is now trading at $48.82.
View the best growth stocks for 2022 here
.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our TNDM earnings forecast
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its earnings results on Wednesday, November, 3rd. The medical device company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.01. The medical device company earned $179.63 million during the quarter, compared to the consensus estimate of $172.80 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 2.99% and a negative net margin of 1.72%. During the same period in the previous year, the firm posted ($0.09) earnings per share.

When did Tandem Diabetes Care's stock split?

Shares of Tandem Diabetes Care reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $835.00 million-$845.00 million, compared to the consensus revenue estimate of $857.12 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (10.07%), State Street Corp (2.68%), Stephens Investment Management Group LLC (1.31%), Macquarie Group Ltd. (1.03%), Price T Rowe Associates Inc. MD (0.99%) and Voya Investment Management LLC (0.81%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends
.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $48.82.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $3.14 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

The company employs 2,000 workers across the globe.

When was Tandem Diabetes Care founded?

Tandem Diabetes Care was founded in 2006.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.